MetaCap

ProKidney (PROK) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Valneva (VALN) has outperformed ProKidney (PROK) over the past year, losing 40.1% versus a loss of 52.5%. Over five years, PROK leads with a -89.5% price change compared with -91.3% for VALN. Valneva is the larger company by market cap ($490.9 million vs $415.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PROK-52.51%VALN-40.14%
+44%-7%-57%
Nov 21, 20251 yearNov 20, 2026
PROK-89.52%VALN-89.45%
+37%-32%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PROK versus VALN key metrics
MetricPROKVALN
Share price$1.04$5.16
Market cap$415.21M$490.86M
1-day change-1.89%-3.82%
YTD return-53.57%-41.50%
1-year return-52.51%-40.14%
5-year return-89.49%-91.34%
Forward P/E—4.34
EPS (TTM)$-0.61$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$893.00K—
Revenue growth (YoY)+1075.00%—
Net income (latest FY)$-68.99M—
Operating margin-18477.83%—
Net margin-7725.20%—
52-week high$2.65$12.18
52-week low$0.87$4.75
Distance from 52-week high-60.75%-57.64%
Analyst consensusbuynone
Avg. price target upside+525.00%+137.98%
Average volume1.44M23.10K
Shares outstanding209.63M95.13M
Employees231620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VALN has outperformed PROK by 12.4 percentage points over the past year.

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

PROK vs VALN FAQ

Which is bigger, ProKidney or Valneva?

Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $415.21M for ProKidney (PROK).

Which stock has performed better over the past year, PROK or VALN?

VALN returned -40.14% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.

Are ProKidney and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons